gi5yylhx

Property	Value
?:abstract	OBJECTIVE: Coagulopathy is one of the characteristics observed in critically ill patients with coronavirus disease 2019 (COVID-19). Antiphospholipid antibodies (aPLs) contribute to coagulopathy, though their role in COVID-19 remains unclear. This study was undertaken to determine the prevalence and characteristics of aPLs in patients with COVID-19. METHODS: Sera collected from 66 COVID-19 patients who were critically ill and 13 COVID-19 patients who were not critically ill were tested by chemiluminescence immunoassay for anticardiolipin antibodies (aCLs), anti-ß2 -glycoprotein I (anti-ß2 GPI) (IgG, IgM, and IgA), and IgG anti-ß2 GPI-domain 1 (anti-ß2 GPI-D1) and IgM and IgG anti-phosphatidylserine/prothrombin (anti-PS/PT) antibodies were detected in the serum by enzyme-linked immunosorbent assay. RESULTS: Of the 66 COVID-19 patients in critical condition, aPLs were detected in 31 (47% ). Antiphospholipid antibodies were not present among COVID-19 patients who were not in critical condition. The IgA anti-ß2 GPI antibody was the most commonly observed aPL in patients with COVID-19 and was present in 28.8% (19 of 66) of the critically ill patients, followed by IgA aCLs (17 of 66, or 25.8%) and IgG anti-ß2 GPI (12 of 66, or 18.2%). For multiple aPLs, IgA anti-ß2 GPI + IgA aCLs was the most common antibody profile observed (15 of 66, or 22.7%), followed by IgA anti-ß2 GPI + IgA aCL + IgG anti-ß2 GPI (10 of 66, or 15.2%). Antiphospholipid antibodies emerge ~35-39 days after disease onset. A dynamic analysis of aPLs revealed 4 patterns based on the persistence or transient appearance of the aPLs. Patients with multiple aPLs had a significantly higher incidence of cerebral infarction compared to patients who were negative for aPLs (P = 0.023). CONCLUSION: Antiphospholipid antibodies were common in critically ill patients with COVID-19. Repeated testing demonstrating medium to high titers of aPLs and the number of aPL types a patient is positive for may help in identifying patients who are at risk of developing cerebral infarction. Antiphospholipid antibodies may be transient and disappear within a few weeks, but in genetically predisposed patients, COVID-19 may trigger the development of an autoimmune condition similar to the antiphospholipid syndrome (APS), referred to as \'COVID-19-induced APS-like syndrome.\' Long-term follow-up of COVID-19 patients who are positive for aPLs would be of great importance in understanding the pathogenesis of this novel coronavirus.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/gi5yylhx_hasAnnotation_C0031623>
?:creator	<https://research.tib.eu/covid-19/entity/Xiao%2C_Meng%3B_Zhang%2C_Yan%3B_Zhang%2C_Shulan%3B_Qin%2C_Xuzhen%3B_Xia%2C_Peng%3B_Cao%2C_Wei%3B_Jiang%2C_Wei%3B_Chen%2C_Huan%3B_Ding%2C_Xin%3B_Zhao%2C_Hua%3B_Zhang%2C_Hongmin%3B_Wang%2C_Chunyao%3B_Zhao%2C_Jing%3B_Sun%2C_Xuefeng%3B_Tian%2C_Ran%3B_Wu%2C_Wei%3B_Wu%2C_Dong%3B_Ma%2C_Jie%3B_Chen%2C_Yu%3B_Zhang%2C_Dong%3B_Xie%2C_Jing%3B_Yan%2C_Xiaowei%3B_Zhou%2C_Xiang%3B_Liu%2C_Zhengyin%3B_Wang%2C_Jinglan%3B_Du%2C_Bin%3B_Qin%2C_Yan%3B_Gao%2C_Peng%3B_Lu%2C_Minya%3B_Hou%2C_Xin%3B_Wu%2C_Xian%3B_Zhu%2C_Huadong%3B_Xu%2C_Yingchun%3B_Zhang%2C_Wen%3B_Li%2C_Taisheng%3B_Zhang%2C_Fengchun%3B_Zhao%2C_Yongqiang%3B_Li%2C_Yongzhe%3B_Zhang%2C_Shuyang>
?:journal	Arthritis_Rheumatol
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/gi5yylhx_HAS_C0162595_ASSOCIATED_WITH_C0012634> <https://research.tib.eu/covid-19/entity/gi5yylhx_HAS_C0162595_PREDISPOSES_C0005779> <https://research.tib.eu/covid-19/entity/gi5yylhx_HAS_C5203670_CAUSES_C0004364> <https://research.tib.eu/covid-19/entity/gi5yylhx_HAS_C5203670_CAUSES_C0085278>
?:source	WHO
?:title	Antiphospholipid Antibodies in Critically Ill Patients With COVID-19
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#880254
?:year	2020

Property

Value

?:abstract

OBJECTIVE: Coagulopathy is one of the characteristics observed in critically ill patients with coronavirus disease 2019 (COVID-19). Antiphospholipid antibodies (aPLs) contribute to coagulopathy, though their role in COVID-19 remains unclear. This study was undertaken to determine the prevalence and characteristics of aPLs in patients with COVID-19. METHODS: Sera collected from 66 COVID-19 patients who were critically ill and 13 COVID-19 patients who were not critically ill were tested by chemiluminescence immunoassay for anticardiolipin antibodies (aCLs), anti-ß2 -glycoprotein I (anti-ß2 GPI) (IgG, IgM, and IgA), and IgG anti-ß2 GPI-domain 1 (anti-ß2 GPI-D1) and IgM and IgG anti-phosphatidylserine/prothrombin (anti-PS/PT) antibodies were detected in the serum by enzyme-linked immunosorbent assay. RESULTS: Of the 66 COVID-19 patients in critical condition, aPLs were detected in 31 (47% ). Antiphospholipid antibodies were not present among COVID-19 patients who were not in critical condition. The IgA anti-ß2 GPI antibody was the most commonly observed aPL in patients with COVID-19 and was present in 28.8% (19 of 66) of the critically ill patients, followed by IgA aCLs (17 of 66, or 25.8%) and IgG anti-ß2 GPI (12 of 66, or 18.2%). For multiple aPLs, IgA anti-ß2 GPI + IgA aCLs was the most common antibody profile observed (15 of 66, or 22.7%), followed by IgA anti-ß2 GPI + IgA aCL + IgG anti-ß2 GPI (10 of 66, or 15.2%). Antiphospholipid antibodies emerge ~35-39 days after disease onset. A dynamic analysis of aPLs revealed 4 patterns based on the persistence or transient appearance of the aPLs. Patients with multiple aPLs had a significantly higher incidence of cerebral infarction compared to patients who were negative for aPLs (P = 0.023). CONCLUSION: Antiphospholipid antibodies were common in critically ill patients with COVID-19. Repeated testing demonstrating medium to high titers of aPLs and the number of aPL types a patient is positive for may help in identifying patients who are at risk of developing cerebral infarction. Antiphospholipid antibodies may be transient and disappear within a few weeks, but in genetically predisposed patients, COVID-19 may trigger the development of an autoimmune condition similar to the antiphospholipid syndrome (APS), referred to as \'COVID-19-induced APS-like syndrome.\' Long-term follow-up of COVID-19 patients who are positive for aPLs would be of great importance in understanding the pathogenesis of this novel coronavirus.

is ?:annotates of